References in periodicals archive ?
Altered expression of plasminogen activator inhibitor type 1 in placentas from pregnant women with preeclampsia and/or intrauterine fetal growth retardation," Blood, vol.
The serine protease urokinase-type plasminogen activator (uPA) and its inhibitor, plasminogen activator inhibitor type 1 (PAI-1), is one example of potential prognostic breast cancer biomarkers.
Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1.
Harbeck N, Kates RE, Schmitt M, Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualised therapy decisions in primary breast cancer is greatest when used in combination.
Low tPA activity in the blood is typically associated with increased plasminogen activator inhibitor type 1 (PAI-1) and may be related to an increase risk of arterial thrombosis (1-3).
The fibrinolytic activity of blood depends on the balance between the circulating concentrations of tissue-type plasminogen activator (t-PA) (4) and plasminogen activator inhibitor type 1 (PAI-1), which are both secreted by endothelial cells [2].
Measurement of the protein components of the urokinase system in tumor extracts reveals that high concentrations of uPA, uPAR, and plasminogen activator inhibitor type 1 (PAI-1) are associated with shorter survival of breast cancer patients [16-23], and therefore may be used as prognostic markers.
Full browser ?